These challenges underscore the significance of our preclinical findings which indicate that T‐DXd can delay tumor progression in HNSCC, especially noteworthy given the drug's breakthrough therapy designation by the FDA in August 2023 for unresectable or metastatic HER2‐positive solid tumors without satisfactory alternative treatments, and for HER2‐positive metastatic colorectal cancer patients after ≥ 2 prior regimens. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.